Anti-TNF-alfa Therapy May Not İmprove Arterial Stiffness in Patients With As: A 24 Week Follow Up
 
Yazarlar (8)
Erhan Çapkın Karadeniz Teknik Üniversitesi, Türkiye
Murat Karkucak Karadeniz Teknik Üniversitesi, Türkiye
Abdulkadir Kırış
Karadeniz Teknik Üniversitesi, Türkiye
İsmet Durmuş Karadeniz Teknik Üniversitesi, Türkiye
Adem Karaca Erzincan Üniversitesi, Türkiye
Mehmet Tosun
Ahmet Ayar Karadeniz Teknik Üniversitesi, Türkiye
Makale Türü Özgün Makale (SSCI, AHCI, SCI, SCI-Exp dergilerinde yayınlanan tam makale)
Dergi Adı Rheumatology (Q4)
Dergi ISSN 1462-0324 Wos Dergi Scopus Dergi
Dergi Tarandığı Indeksler SCI-Expanded
Makale Dili İngilizce Basım Tarihi 04-2012
Cilt / Sayı / Sayfa 51 / 5 / 910–914 DOI 10.1093/rheumatology/ker434
Makale Linki http://www.rheumatology.oxfordjournals.org/cgi/doi/10.1093/rheumatology/ker434
Özet
Objective. The availability of new-generation drugs has provided significant success reflected by disease activity markers and clinical status in AS, but controversial reports necessitate further assessment of associated increased risk of cardiovascular burden that might persist. Hence this prospective clinical study evaluated the effectiveness of a 24-week anti-TNF-α therapy on vascular stiffness [pulse wave velocity (PWV)] in AS. Methods. A total of 28 active AS patients (21 males, 7 females) were enrolled before the start of biologic therapy. Demographic and clinical characteristics were recorded. Arterial stiffness was assessed using PWV. Patients were evaluated before and 24 weeks after anti-TNF-α therapy. Results. The mean disease duration was 8.4 (4.9) years. After 24 weeks of anti-TNF-α therapy, despite significant improvements in patients’ symptoms and clinical activity …
Anahtar Kelimeler
BM Sürdürülebilir Kalkınma Amaçları
Atıf Sayıları
Google Scholar 56
Anti-TNF-alfa Therapy May Not İmprove Arterial Stiffness in Patients With As: A 24 Week Follow Up

Paylaş